Drug Profile
Research programme: skeletal muscle atrophy therapeutics - Emmyon
Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Emmyon
- Class Small molecules
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Muscular atrophy
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Muscular atrophy (In the elderly) in USA
- 30 Sep 2018 Preclinical development is ongoing in USA
- 30 Sep 2018 Emmyon receives SBIR grant from National Institute on Aging for development in Muscular atrophy (In the elderly)